Small Pharmaceuticals
Market Cap
₹15,370 ₹15,370 Cr.
P/E
13.43
PEG
4.33
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

Base-case growth is driven by 2–3 successful Para IV exclusivity launches and steady scaling in Brazil/Adcock, recovering from the FY27 Revlimid trough.

Bull case triggers if 3+ sole‑FTF exclusivities materialize and Semaglutide US advances, accelerating the earnings bridge well above the base path.

Bear case materializes when Para IV approvals stall >12 months and US pricing intensifies, keeping revenue near the post‑Revlimid floor and delaying margin recovery.

Financial

Business

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material